Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I.

Skottner A, Clark RG, Fryklund L, Robinson IC

Endocrinology1 May 1989Cited by 64 (Europe PMC)

PMID2707163DOI10.1210/endo-124-5-2519PepBankPUB-02707163

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I increased serum IGF-I to 713 +/- 20 ng/ml versus 395 +/- 31 ng/ml with saline.
In plain wordsIn rats, hIGF-I increased serum IGF-I compared with saline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseSerum IGF-I
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
Saline infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
180 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Infusions of hIGF-I at 180 micrograms/day for 9 days elevated serum IGF-I concentrations significantly over those in the saline-infused controls (713 +/- 20 ng/ml vs. 395 +/- 31 ng/ml); hGH infusions did not raise IGF-I levels significantly (435 +/- 20 ng/ml).
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716301
02AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH did not significantly increase serum IGF-I, measured at 435 +/- 20 ng/ml.
In plain wordsIn rats, hGH did not significantly increase serum IGF-I compared with saline.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum IGF-I
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
Saline infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Infusions of hIGF-I at 180 micrograms/day for 9 days elevated serum IGF-I concentrations significantly over those in the saline-infused controls (713 +/- 20 ng/ml vs. 395 +/- 31 ng/ml); hGH infusions did not raise IGF-I levels significantly (435 +/- 20 ng/ml).
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716302
03AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, high-dose hIGF-I increased free IGF concentrations.
In plain wordsIn rats, high-dose hIGF-I increased free IGF concentrations.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseFree IGF concentrations
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
180 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Gel filtration of serum samples showed that the high-dose hIGF-I infusions increased free IGF concentrations, without apparently altering the pattern of IGF-I binding whereas hGH infusions increased the amount of high mol wt IGF-I binding protein.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716303
04AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I apparently did not alter the IGF-I binding pattern.
In plain wordsIn rats, hIGF-I apparently did not alter the IGF-I binding pattern.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableIGF-I binding pattern
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
180 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Gel filtration of serum samples showed that the high-dose hIGF-I infusions increased free IGF concentrations, without apparently altering the pattern of IGF-I binding whereas hGH infusions increased the amount of high mol wt IGF-I binding protein.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716304
05AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH increased high molecular weight IGF-I binding protein.
In plain wordsIn rats, hGH increased high molecular weight IGF-I binding protein.
Peptide
HGH (somatotropin)
Outcome
IncreaseHigh molecular weight IGF-I binding protein
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Gel filtration of serum samples showed that the high-dose hIGF-I infusions increased free IGF concentrations, without apparently altering the pattern of IGF-I binding whereas hGH infusions increased the amount of high mol wt IGF-I binding protein.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716305
06AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, IGF-I infusion did not affect pituitary rat GH amounts.
In plain wordsIn rats, IGF-I infusion did not affect pituitary rat GH amounts.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changePituitary rat GH
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Neither IGF-I nor hGH infusions affected the small amounts of rat GH present in the dwarf rat pituitary glands.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716306
07AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH infusion did not affect pituitary rat GH amounts.
In plain wordsIn rats, hGH infusion did not affect pituitary rat GH amounts.
Peptide
HGH (somatotropin)
Outcome
No significant changePituitary rat GH
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Neither IGF-I nor hGH infusions affected the small amounts of rat GH present in the dwarf rat pituitary glands.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716307
08AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH increased weight gain to 2.1 +/- 0.2 g/day versus 1.2 +/- 0.3 g/day with saline.
In plain wordsIn rats, hGH increased body weight gain compared with saline.
Peptide
HGH (somatotropin)
Outcome
IncreaseBody weight gain
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
Saline infusion
Outcome group
Body weight · Metabolic and weight
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Continuous iv infusions of hGH (200 mU/day for 9 days) stimulated body wt gain (2.1 +/- 0.2 g/day) and bone growth (96 +/- 9 microns/day) significantly compared to saline-infused dwarf rats (1.2 +/- 0.3 g/day and 43 +/- 3 microns/day).
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716308
09AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH increased bone growth to 96 +/- 9 microns/day versus 43 +/- 3 microns/day with saline.
In plain wordsIn rats, hGH increased bone growth compared with saline.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone growth
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
Saline infusion
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Continuous iv infusions of hGH (200 mU/day for 9 days) stimulated body wt gain (2.1 +/- 0.2 g/day) and bone growth (96 +/- 9 microns/day) significantly compared to saline-infused dwarf rats (1.2 +/- 0.3 g/day and 43 +/- 3 microns/day).
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716309
10AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I produced weight gain of 2.1 +/- 0.5 g/day, similar to 2.1 +/- 0.2 g/day with hGH.
In plain wordsIn rats, hIGF-I produced body weight gain similar to hGH infusion.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableBody weight gain
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
hGH infusion
Outcome group
Body weight · Endocrine and hormones
Studied dose
180 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Infusions of hIGF-I at 180 micrograms/day produced a body wt gain (2.1 +/- 0.5 g/day) similar to that seen in the hGH-infused group but a significantly smaller stimulation of bone growth (63 +/- 3 microns/day).
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716310
11AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I produced bone growth of 63 +/- 3 microns/day, significantly less than 96 +/- 9 microns/day with hGH.
In plain wordsIn rats, hIGF-I stimulated less bone growth than hGH infusion.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseBone growth
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
hGH infusion
Outcome group
Bone and joint · Musculoskeletal
Studied dose
180 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Infusions of hIGF-I at 180 micrograms/day produced a body wt gain (2.1 +/- 0.5 g/day) similar to that seen in the hGH-infused group but a significantly smaller stimulation of bone growth (63 +/- 3 microns/day).
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716311
12AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I at 36 micrograms/day did not affect body weight gain.
In plain wordsIn rats, hIGF-I at 36 micrograms/day did not affect body weight.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBody weight gain
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Body weight · Endocrine and hormones
Studied dose
36 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Infusion of a 5-fold lower dose of hIGF-I (36 micrograms/day for 9 days) had no effect on body wt or bone growth.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716312
13AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I at 36 micrograms/day did not affect bone growth.
In plain wordsIn rats, hIGF-I at 36 micrograms/day did not affect bone growth.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBone growth
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Bone and joint · Musculoskeletal
Studied dose
36 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Infusion of a 5-fold lower dose of hIGF-I (36 micrograms/day for 9 days) had no effect on body wt or bone growth.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716313
14AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I did not affect food intake.
In plain wordsIn rats, hIGF-I did not affect food intake.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeFood intake
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Food intake was unaffected by either hGH or hIGF-I infusions.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716314
15AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH did not affect food intake.
In plain wordsIn rats, hGH did not affect food intake.
Peptide
HGH (somatotropin)
Outcome
No significant changeFood intake
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
Food intake was unaffected by either hGH or hIGF-I infusions.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716315
16AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hGH induced relatively proportional growth in most organs studied.
In plain wordsIn rats, hGH induced relatively proportional growth in most organs studied.
Peptide
HGH (somatotropin)
Outcome
IncreaseOrgan growth pattern
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
hGH induced a relatively proportional growth in most of the organs studied, whereas hIGF-I infusion at 180 micrograms/day stimulated a disproportionately greater growth of the kidney, adrenals, and spleen.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716316
17AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, hIGF-I stimulated disproportionately greater growth of the kidney, adrenals, and spleen.
In plain wordsIn rats, hIGF-I stimulated disproportionately greater growth of the kidney, adrenals, and spleen.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseOrgan growth pattern
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
180 micrograms/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
hGH induced a relatively proportional growth in most of the organs studied, whereas hIGF-I infusion at 180 micrograms/day stimulated a disproportionately greater growth of the kidney, adrenals, and spleen.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716317
18AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, liver IGF-I amounts were similar after IGF-I infusion, hGH infusion, and control treatment.
In plain wordsIn rats, liver IGF-I amounts were similar after IGF-I infusion, hGH infusion, and control treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableLiver IGF-I
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
Control and hGH infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
the amounts of IGF-I in the liver were similar in control, hGH, or IGF-I-infused animals,
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716318
19AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, liver IGF-I amounts were similar after hGH infusion, IGF-I infusion, and control treatment.
In plain wordsIn rats, liver IGF-I amounts were similar after hGH infusion, IGF-I infusion, and control treatment.
Peptide
HGH (somatotropin)
Outcome
Not applicableLiver IGF-I
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
Control and IGF-I infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
200 mU/day · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
the amounts of IGF-I in the liver were similar in control, hGH, or IGF-I-infused animals,
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716319
20AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, IGF-I infusion produced more kidney immunoreactive IGF-I than hGH treatment.
In plain wordsIn rats, IGF-I infusion produced more kidney immunoreactive IGF-I than hGH treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseKidney immunoreactive IGF-I
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
hGH-treated rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
whereas kidney and adrenals from IGF-I infused animals contained larger amounts of immunoreactive IGF-I than did those tissues from hGH-treated rats.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716320
21AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, IGF-I infusion produced more adrenal immunoreactive IGF-I than hGH treatment.
In plain wordsIn rats, IGF-I infusion produced more adrenal immunoreactive IGF-I than hGH treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseAdrenal immunoreactive IGF-I
Study
ratn: not reported in source
GH-deficient mutant dwarf rat
Comparator
hGH-treated rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenous infusion · 9 daysAs given in this study (rat).
Source sentences
Summary
whereas kidney and adrenals from IGF-I infused animals contained larger amounts of immunoreactive IGF-I than did those tissues from hGH-treated rats.
1 context sentence(design, population, supporting numbers)
Summary · context
A new mutant GH-deficient dwarf rat has been used to study the effects of iv infusions of human GH (hGH) and recombinant human insulin-like growth factor I (hIGF-I).
Report a problemFND-0270716321

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.